Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Mandy Francis

Nurse Practitioner, Family Wesley Chapel, FL Nurse Practitioner

NPI 1306270640 CMS profile 10509438

2014 Ashley Oaks Cir Ste 102, Wesley Chapel, FL 33544

Open in the dashboard

General payments

$8,157

145 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mandy Francis of Wesley Chapel, FL is reported in the CMS Open Payments database as having received $8,157 across 145 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $244 4
2023 General $19 1
2022 General $289 9
2021 General $7,606 131

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mandy Francis
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Mandy Francis were reported at $244. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Mandy Francis Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $7,606 $124 $35–$379 $132
2022 $289 $141 $44–$430 $149
2023 $19 $154 $49–$476 $160
2024 $0 $165 $51–$504 $164
2025 $244 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Biodelivery Sciences International, Inc. $4,998 29 payments
  2. Biohaven Pharmaceuticals, Inc. $1,089 15 payments
  3. AbbVie, Inc. $360 22 payments
  4. Boston Scientific Corporation $303 7 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $160 7 payments
  6. Scilex Pharmaceuticals Inc. $151 9 payments
  7. Teva Pharmaceuticals USA, Inc. $143 7 payments
  8. Collegium Pharmaceutical, Inc. $140 9 payments
  9. Amgen Inc. $109 6 payments
  10. Tonix Pharmaceuticals, Inc. $94 1 payment
  11. Other $609 33 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,641 4 payments
  2. Food and Beverage $2,591 136 payments
  3. Travel and Lodging $1,125 4 payments
  4. Consulting Fee $800 1 payment
Products named General payments · program years 2021–2025
  1. BELBUCA $4,981 27 payments
  2. SYMPROIC $4,295 8 payments
  3. NURTEC ODT $1,089 15 payments
  4. WaveWriter Alpha Prime 16 $238 6 payments
  5. UBRELVY $235 15 payments
  6. RELISTOR $160 7 payments
  7. ZTLido $151 9 payments
  8. AJOVY $143 7 payments
  9. AIMOVIG $133 8 payments
  10. QULIPTA $126 7 payments
  11. Other $1,186 59 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

438

Median for Nurse Practitioner: 389

Drug cost

$66,116

Median for Nurse Practitioner: $21,885

Branded share of claims

86.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 367 $63,549
Naloxone Hcl Generic 27 $2,088
Naltrexone Hcl Generic 19 $431
Trazodone Hcl Generic 13 $37
Citalopram Hbr Citalopram Hydrobromide Brand 12 $10

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Records

145 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record